Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05525247 · ClinicalTrials.gov registry record · Phase 1

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination

A Phase 1 study of Advanced Solid Tumor, sponsored by Selecxine.

Recruiting
Registry status
Phase 1
Development phase
420
Enrollment target
9
Study locations

NCT05525247 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Selecxine. The registered enrollment target is 420 participants, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (120% higher). The trial reports 9 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05525247, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Selecxine.

RECRUITING
Registry status
Phase 1
Development phase
420 participants
Enrollment target
9
Study locations

Study Summary

This is a Phase 1/2, open-label, multicenter, dose escalation and expansion study, evaluating the safety, tolerability, pharmacokinetic, preliminary anti-tumor activity, and effects on pharmacodynamic markers following administration of SLC-3010 as monotherapy and in combination with gemcitabine, in patients with various advanced solid tumors.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG SLC-3010
  • COMBINATION_PRODUCT Gemcitabine

Study Locations (9)

Florida

  • Selecxine Investigator site - Sarasota

Michigan

  • Selecxine Investigator site - Detroit

Oklahoma

  • Selecxine Investigator site - Oklahoma City

New South Wales

  • Selecxine Investigator site - Waratah

Perth

  • Selecxine Investigator site - Brentwood

Jongno-gu

  • Selecxine Investigator site - Seoul

Seodaemun-gu

  • Selecxine Investigator site - Seoul

Seongnam-si

  • Selecxine Investigator site - Gyeonggi-do

Trial Details

FieldValue
Enrollment Target 420 participants
Start Date 2022-12-21
Est. Completion 2028-01
Phase Phase 1

Sponsor

Selecxine

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05525247

The ClinicalTrials.gov registry entry for NCT05525247 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 420 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (120% higher). The listed sponsor is Selecxine, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which SLC-3010 is the first listed.

NCT05525247 reports 9 study locations spanning 9 distinct geographic areas - top geographies include Florida, Michigan, Oklahoma.

Frequently Asked Questions

What is clinical trial NCT05525247 about?

NCT05525247 is a clinical study titled "A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination". This is a Phase 1/2, open-label, multicenter, dose escalation and expansion study, evaluating the safety, tolerability, pharmacokinetic, preliminary anti-tumor activity, and effects on pharmacodynamic markers following administration of SLC-3010 as monotherapy and in combination with gemcitabine, in...

What is the current status of trial NCT05525247?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 420 participants. The study started on 2022-12-21. Estimated completion is 2028-01.

What conditions does trial NCT05525247 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT05525247?

The interventions under investigation include: SLC-3010 (DRUG), Gemcitabine (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT05525247?

This trial is sponsored by Selecxine, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05525247 being conducted?

This trial has 9 study locations across Florida, Michigan, Oklahoma, New South Wales, Perth. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.